#KO
### π’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - ν¨λ¥ λ° ν¨κ³Ό
* μ΄ μ•½μ€ κ³„μ μ„± λ° λ‹¤λ…„μ„± μ•λ λ¥΄κΈ°μ„± λΉ„μ—Ό, μ•λ λ¥΄κΈ°μ„± κ²°λ§‰μ—Ό, λ§μ„± νΉλ°μ„± λ‘λ“λ¬κΈ°, ν”Όλ¶€μ†μ–‘μ¦κ³ΌΒ ν•μ΄λ“λ΅μ½”ν‹°μ† μ™Έμ©μ μ™€ λ³‘μ©μ— μν• μµμ§„, ν”Όλ¶€μ—Όμ— μ‚¬μ©ν•©λ‹λ‹¤.

### π•’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - μ©λ²• λ° μ©λ‰
* μ„±μΈ λ° 6μ„Έ μ΄μƒμ μ†μ•„λ” 1μΌ 1ν 1μ •(10 mg)μ„ μ·¨μΉ¨ μ „μ— λ³µμ©ν•κ³ , μ΄μƒλ°μ‘μ— λ―Όκ°ν• ν™μμ κ²½μ°λ” 1/2μ •(5 mg)μ”©μ„ μ•„μΉ¨, μ €λ…μ— λ¶„ν•  λ³µμ©ν•©λ‹λ‹¤.

μ—°λ Ή, μ¦μƒμ— λ”°λΌ μ μ ν μ¦κ°ν•©λ‹λ‹¤.

μ¤‘λ“±λ„~μ¤‘μ¦(μ‹¬ν• μ¦μƒ)μ μ‹ μ¥μ•  ν™μμ ν¬μ—¬ κ°„κ²©μ€ ν™μμ μ‹ κΈ°λ¥μ— λ”°λΌ μ΅°μ λμ–΄μ•Ό ν•κ³ , μ‹ μ¥μ• λ¥Ό κ°€μ§„ μ†μ•„ ν™μλ” ν™μμ μ‹  μ²­μ†μ¨κ³Ό μ²΄μ¤‘μ„ κ³ λ ¤ν•μ—¬ κ°λ³„μ μΌλ΅ μ©λ‰μ„ μ΅°μ ν•΄μ•Ό ν•λ―€λ΅ μμ„Έν• μ‚¬ν•­μ€ ν—κ°€μ‚¬ν•­μ„ μ°Έκ³ ν•μ‹­μ‹μ¤.

### β οΈ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - μ£Όμμ‚¬ν•­
* μ •λ³΄ μ—†μ
* μ΄ μ•½Β λ° νλ“λ΅μ‹μ§„ λλ” ν”ΌνλΌμ§„ μ λ„μ²΄μ— κ³Όλ―Όμ¦ ν™μ, μ‹ λ¶€μ „, 6μ„Έ λ―Έλ§μ μ μ•„,Β κ°λ½ν† μ¤μ¤ λ¶λ‚΄μ„±, Lapp μ λ‹Ήλ¶„ν•΄ν¨μ† κ²°ν•μ¦ λλ” ν¬λ„λ‹Ή-κ°λ½ν† μ¤μ¤ ν΅μμ¥μ•  λ“±μ μ μ „μ μΈ λ¬Έμ κ°€ μλ” ν™μλ” μ΄ μ•½μ„ λ³µμ©ν•μ§€ λ§μ‹­μ‹μ¤.

μ΄ μ•½μ„ λ³µμ©ν•κΈ° μ „μ— μ„λ¶€, μμ λ¶€, μ‹ μ¥μ• (μ‹ μ¥μ¥μ• ), κ°„μ¥μ• , λ…ΈμΈ,Β κ°„μ§ ν™μ λ° λ°μ‘ μ„ν—μ„±μ΄ μλ” ν™μ,Β μ†λ³€κ³ μ„μ μ„ ν–‰μ”μΈ(μ²™μ λ³‘λ³€, μ „λ¦½μ„  λΉ„λ€μ¦ λ“±)μ΄ μλ” ν™μλ” μμ‚¬ λλ” μ•½μ‚¬μ™€ μƒμν•μ‹­μ‹μ¤.

#KO
### π’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - ν¨λ¥ λ° ν¨κ³Ό
* μ΄ μ•½μ€ κ³„μ μ„± λ° λ‹¤λ…„μ„± μ•λ λ¥΄κΈ°μ„± λΉ„μ—Ό, μ•λ λ¥΄κΈ°μ„± κ²°λ§‰μ—Ό, λ§μ„± νΉλ°μ„± λ‘λ“λ¬κΈ°, ν”Όλ¶€μ†μ–‘μ¦κ³ΌΒ ν•μ΄λ“λ΅μ½”ν‹°μ† μ™Έμ©μ μ™€ λ³‘μ©μ— μν• μµμ§„, ν”Όλ¶€μ—Όμ— μ‚¬μ©ν•©λ‹λ‹¤.

### π•’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - μ©λ²• λ° μ©λ‰
* μ„±μΈ λ° 6μ„Έ μ΄μƒμ μ†μ•„λ” 1μΌ 1ν 1μ •(10 mg)μ„ μ·¨μΉ¨ μ „μ— λ³µμ©ν•κ³ , μ΄μƒλ°μ‘μ— λ―Όκ°ν• ν™μμ κ²½μ°λ” 1/2μ •(5 mg)μ”©μ„ μ•„μΉ¨, μ €λ…μ— λ¶„ν•  λ³µμ©ν•©λ‹λ‹¤.

μ—°λ Ή, μ¦μƒμ— λ”°λΌ μ μ ν μ¦κ°ν•©λ‹λ‹¤.

μ¤‘λ“±λ„~μ¤‘μ¦(μ‹¬ν• μ¦μƒ)μ μ‹ μ¥μ•  ν™μμ ν¬μ—¬ κ°„κ²©μ€ ν™μμ μ‹ κΈ°λ¥μ— λ”°λΌ μ΅°μ λμ–΄μ•Ό ν•κ³ , μ‹ μ¥μ• λ¥Ό κ°€μ§„ μ†μ•„ ν™μλ” ν™μμ μ‹  μ²­μ†μ¨κ³Ό μ²΄μ¤‘μ„ κ³ λ ¤ν•μ—¬ κ°λ³„μ μΌλ΅ μ©λ‰μ„ μ΅°μ ν•΄μ•Ό ν•λ―€λ΅ μμ„Έν• μ‚¬ν•­μ€ ν—κ°€μ‚¬ν•­μ„ μ°Έκ³ ν•μ‹­μ‹μ¤.

### β οΈ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - μ£Όμμ‚¬ν•­
* μ •λ³΄ μ—†μ
* μ΄ μ•½Β λ° νλ“λ΅μ‹μ§„ λλ” ν”ΌνλΌμ§„ μ λ„μ²΄μ— κ³Όλ―Όμ¦ ν™μ, μ‹ λ¶€μ „, 6μ„Έ λ―Έλ§μ μ μ•„,Β κ°λ½ν† μ¤μ¤ λ¶λ‚΄μ„±, Lapp μ λ‹Ήλ¶„ν•΄ν¨μ† κ²°ν•μ¦ λλ” ν¬λ„λ‹Ή-κ°λ½ν† μ¤μ¤ ν΅μμ¥μ•  λ“±μ μ μ „μ μΈ λ¬Έμ κ°€ μλ” ν™μλ” μ΄ μ•½μ„ λ³µμ©ν•μ§€ λ§μ‹­μ‹μ¤.

μ΄ μ•½μ„ λ³µμ©ν•κΈ° μ „μ— μ„λ¶€, μμ λ¶€, μ‹ μ¥μ• (μ‹ μ¥μ¥μ• ), κ°„μ¥μ• , λ…ΈμΈ,Β κ°„μ§ ν™μ λ° λ°μ‘ μ„ν—μ„±μ΄ μλ” ν™μ,Β μ†λ³€κ³ μ„μ μ„ ν–‰μ”μΈ(μ²™μ λ³‘λ³€, μ „λ¦½μ„  λΉ„λ€μ¦ λ“±)μ΄ μλ” ν™μλ” μμ‚¬ λλ” μ•½μ‚¬μ™€ μƒμν•μ‹­μ‹μ¤.

---

#EN
### π’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - Indications and Effects
* This medicine is used for seasonal and perennial allergic rhinitis, allergic conjunctivitis, chronic idiopathic urticaria, pruritus, and for eczema and dermatitis when used in combination with hydrocortisone topical preparations.

### π•’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - Dosage and Administration
* Adults and children aged 6 years and older should take 1 tablet (10 mg) once daily before bedtime. For patients sensitive to adverse reactions, take 1/2 tablet (5 mg) each in the morning and evening, divided.

Dosage may be appropriately increased or decreased depending on age and symptoms.

For patients with moderate to severe renal impairment, the dosing interval should be adjusted according to the patient's renal function. For pediatric patients with renal impairment, the dose should be individually adjusted considering the patient's renal clearance and body weight. Therefore, please refer to the product insert for detailed information.

### β οΈ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - Precautions
* No information
* Do not take this medicine if you have hypersensitivity to this medicine, hydroxyzine, or piperazine derivatives, renal failure, are an infant under 6 years of age, or have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Before taking this medicine, pregnant women, breastfeeding women, patients with renal impairment, hepatic impairment, the elderly, patients with epilepsy and those at risk of seizures, and patients with predisposing factors for urinary retention (e.g., spinal cord lesion, benign prostatic hyperplasia) should consult a doctor or pharmacist.

---

#CN
### π’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - εζ•εδ½η”¨
* ζ¬θ―η”¨δΊε­£θ‚ζ€§εεΈΈεΉ΄ζ€§θΏ‡ζ•ζ€§ιΌ»η‚γ€θΏ‡ζ•ζ€§η»“θ†η‚γ€ζ…Άζ€§η‰Ήε‘ζ€§θ¨ιΊ»η–Ήγ€η®θ‚¤η™η—’η—‡οΌδ»¥εδΈζ°Άε–ε―η„ζΎε¤–η”¨ε¶ε‰‚θ”εη”¨δΊζΉΏη–Ήγ€η®η‚γ€‚

### π•’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - η”¨ζ³•η”¨ι‡
* ζδΊΊε6ε²δ»¥δΈε„Ώη«¥οΌζ―ζ—¥δΈ€ζ¬΅οΌη΅ε‰ζη”¨1η‰‡οΌ10 mgοΌ‰γ€‚ε―ΉδΊε―ΉδΈθ‰―εεΊ”ζ•ζ„η„ζ‚£θ€…οΌε―ε°†1/2η‰‡οΌ5 mgοΌ‰ε†ζ—©ζ™δΈ¤ζ¬΅ζη”¨γ€‚

η”¨ι‡ε―ζ Ήζ®εΉ΄ιΎ„γ€η—‡η¶ι€‚ε½“εΆε‡γ€‚

ε―ΉδΊδΈ­εΊ¦θ‡³ι‡εΊ¦οΌδΈ¥ι‡η—‡η¶οΌ‰θ‚Ύεθƒ½ζε®³ζ‚£θ€…οΌη»™θ―ι—΄ι”εΊ”ζ Ήζ®ζ‚£θ€…η„θ‚Ύεθƒ½θΏ›θ΅θ°ƒζ•΄γ€‚ε―ΉδΊθ‚Ύεθƒ½ζε®³η„ε„Ώη«¥ζ‚£θ€…οΌεΊ”ζ Ήζ®ζ‚£θ€…η„θ‚ΎζΈ…ι™¤η‡ε’δ½“ι‡δΈδ½“ε–θ°ƒζ•΄ε‰‚ι‡γ€‚ε› ζ­¤οΌθ―¦ζƒ…θ―·ε‚θ€ƒδΊ§ε“θ―΄ζδΉ¦γ€‚

### β οΈ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - ζ³¨ζ„δΊ‹ι΅Ή
* ζ— δΏ΅ζ―
* ε―Ήζ¬θ―εηΎε—ζ–ε“ε—θ΅η”η‰©θΏ‡ζ•η„ζ‚£θ€…γ€θ‚Ύεθƒ½θ΅°η«­ζ‚£θ€…γ€6ε²δ»¥δΈ‹ε©΄εΉΌε„Ώγ€δ»¥εζ‚£ζ‰εδΉ³η³–δΈθ€ε—γ€LappδΉ³η³–ι…¶ηΌΊδΉη—‡ζ–θ‘΅θ„η³–-εδΉ³η³–εΈζ”¶δΈθ‰―η­‰ι—δΌ ζ€§η–Ύη—…η„ζ‚£θ€…θ―·ε‹Ώζη”¨ζ¬θ―γ€‚

ζη”¨ζ¬θ―ε‰οΌε­•ε¦‡γ€ε“ΊδΉ³ζε¦‡ε¥³γ€θ‚Ύεθƒ½ζε®³ζ‚£θ€…οΌθ‚Ύθ„ιηΆοΌ‰γ€θ‚εθƒ½ζε®³ζ‚£θ€…γ€θ€εΉ΄δΊΊγ€η™«η—«ζ‚£θ€…εζ‰η™«η—«ε‘δ½ι£ι™©η„ζ‚£θ€…γ€δ»¥εζ‰ε°Ώζ½΄η•™θ―±ε› οΌε¦‚θ„ι«“η—…εγ€ε‰ε—θ…Ίθ‚¥ε¤§η­‰οΌ‰η„ζ‚£θ€…εΊ”ε’¨θ―Άε»η”ζ–θ―εΈγ€‚

---

#JP
### π’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - εΉθƒ½γƒ»εΉζ
* γ“γ®θ–¬γ―γ€ε­£η―€ζ€§γγ‚γ³ι€εΉ΄ζ€§γ‚Άγƒ¬γƒ«γ‚®γƒΌζ€§ιΌ»η‚γ€γ‚Άγƒ¬γƒ«γ‚®γƒΌζ€§ηµθ†η‚γ€ζ…Άζ€§η‰Ήη™Ίζ€§θ•ιΊ»η–Ήγ€η®θ†ζ»η—’η—‡γ€γγ‚‰γ³γ«γƒ’γƒ‰γƒ­γ‚³γƒ«γƒγ‚Ύγƒ³ε¤–η”¨ε‰¤γ¨γ®δ½µη”¨γ«γ‚γ‚‹ζΉΏη–Ήγ€η®θ†η‚γ«δ½Ώη”¨γ•γ‚γΎγ™γ€‚

### π•’ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - η”¨ζ³•γƒ»η”¨ι‡
* ζδΊΊγγ‚γ³6ζ­³δ»¥δΈγ®ε°ε…γ―γ€1ζ—¥1ε›1ι οΌ10 mgοΌ‰γ‚’ε°±ε―ε‰γ«ζη”¨γ—γ€ε‰―δ½η”¨γ«ζ•ζ„γζ‚£θ€…γ®ε ΄εγ―γ€1/2ι οΌ5 mgοΌ‰γ‚’ζγ¨ε¤•γ«ε†ε‰²γ—γ¦ζη”¨γ—γΎγ™γ€‚

εΉ΄ι½Άγ€η—‡η¶γ«εΏγγ¦ι©ε‡γ«εΆ—ζΈ›γ—γΎγ™γ€‚

δΈ­η­‰εΊ¦γ‹γ‚‰ι‡εΊ¦οΌη—‡η¶γι‡γ„οΌ‰γ®θ…ζ©θƒ½ιε®³ζ‚£θ€…γ«γγ‘γ‚‹ζ•δΈι–“ι”γ―γ€ζ‚£θ€…γ®θ…ζ©θƒ½γ«εΏγγ¦θΏζ•΄γ•γ‚γ‚‹γΉγγ§γ‚γ‚γ€θ…ζ©θƒ½ιε®³γ‚’ζ‰γ™γ‚‹ε°ε…ζ‚£θ€…γ―γ€ζ‚£θ€…γ®θ…γ‚―γƒγ‚Άγƒ©γƒ³γ‚Ήγ¨δ½“ι‡γ‚’θ€ƒζ…®γ—γ¦ε€‹ε¥γ«η”¨ι‡γ‚’θΏζ•΄γ™γ‚‹εΏ…θ¦γγ‚γ‚‹γγ‚γ€θ©³η΄°γ«γ¤γ„γ¦γ―ζ·»δ»ζ–‡ζ›Έγ‚’ε‚η…§γ—γ¦γγ γ•γ„γ€‚

### β οΈ λ‚λ…Έν…μ •(μ„Έν‹°λ¦¬μ§„μ—Όμ‚°μ—Ό) - ζ³¨ζ„δΊ‹ι …
* ζƒ…ε ±γγ—
* γ“γ®θ–¬γγ‚γ³γƒ’γƒ‰γƒ­γ‚­γ‚·γ‚Έγƒ³γΎγγ―γƒ”γƒγƒ©γ‚Έγƒ³θε°δ½“γ«ε―Ύγ—ιζ•η—‡γ®γ‚γ‚‹ζ‚£θ€…γ€θ…δΈε…¨ζ‚£θ€…γ€6ζ­³ζζΊ€γ®δΉ³εΉΌε…γ€γ‚¬γƒ©γ‚―γƒγƒΌγ‚ΉδΈθ€η—‡γ€Lappγƒ©γ‚―γ‚ΏγƒΌγ‚Όζ¬ ζη—‡γΎγγ―γ‚°γƒ«γ‚³γƒΌγ‚Ή-γ‚¬γƒ©γ‚―γƒγƒΌγ‚ΉεΈεδΈθ‰―γγ©γ®ιΊδΌη„ε•ι΅γγ‚γ‚‹ζ‚£θ€…γ―γ€γ“γ®θ–¬γ‚’ζη”¨γ—γγ„γ§γγ γ•γ„γ€‚

γ“γ®θ–¬γ‚’ζη”¨γ™γ‚‹ε‰γ«γ€ε¦ε©¦γ€ζδΉ³ε©¦γ€θ…ζ©θƒ½ιε®³οΌθ…θ‡“ιε®³οΌ‰γ®γ‚γ‚‹ζ‚£θ€…γ€θ‚ζ©θƒ½ιε®³γ®γ‚γ‚‹ζ‚£θ€…γ€ι«ι½Άθ€…γ€γ¦γ‚“γ‹γ‚“ζ‚£θ€…γγ‚γ³η™Ίδ½γ®γƒγ‚Ήγ‚―γγ‚γ‚‹ζ‚£θ€…γ€ε°Ώι–‰γ®η΄ ε› οΌθ„ι«„η—…ε¤‰γ€ε‰η«‹θ…Ίθ‚¥ε¤§η—‡γγ©οΌ‰γγ‚γ‚‹ζ‚£θ€…γ―γ€ε»εΈ«γΎγγ―θ–¬ε‰¤εΈ«γ«γ”η›Έθ«‡γγ γ•γ„γ€‚